## **Listing of Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

## 1.-38. (Canceled)

- 39. (Currently Amended) The method of claim [[38]] 48, wherein said one or more compounds that binds said reverse transcriptase is an azido-labeled compound.
- 40. (Previously Presented) The method of claim 39, wherein said azido-labeled compound is azido dipyrodiazepinona or N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide.
- 41. (Previously Presented) The method of claim 39, wherein said azido-labeled compound is N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide.
- 42. (Currently Amended) The method of claim [[38]] 48, wherein the irradiation is with UV light.
- 43. (Currently Amended) The method of claim [[38]] 48, wherein reverse transcriptase is comprised in an HIV particle.
- 44. (Previously Presented) The method of claim 43, wherein said HIV particle is HIV-1.
- 45. (Previously Presented) The method of claim 44, wherein said HIV-1 is Group M or Group O.
- 46. (Previously Presented) The method of claim 45, wherein said Group M are selected from the group consisting of clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, and clade I.

2

25678754.1

- 47. (Previously Presented) The method of claim 45, wherein said Group M particles are clade B particles.
- 48. (Currently Amended) The method of claim 38, further A method comprising:

  obtaining a reverse transcriptase that has been inactivated by binding said reverse

  transcriptase with one or more compounds and then irradiating said reverse

  transcriptase; and

  administering the inactivated reverse transcriptase to a subject.
- 49. (Currently Amended) The method of claim 48, wherein the subject [[in]] is human.
- 50. (Previously Presented) The method of claim 49, further defined as a method of vaccination.
- 51.-56. (Canceled)